Patents by Inventor Norio Asai
Norio Asai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10710988Abstract: [Problem] To provide a compound useful as an MC4 receptor agonist. [Means for Solution] The present inventors studied MC4 receptor agonists, and have found that a piperazine derivative has an MC4 receptor agonistic action, thereby completing the present invention. The piperazine derivative of the present invention has an MC4 receptor agonistic action, and can be used as an agent for preventing or treating bladder and/or urinary tract diseases, in particular, underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-external urethral sphincter dyssynergia, and voiding dysfunctions in benign prostatic hyperplasia.Type: GrantFiled: July 18, 2017Date of Patent: July 14, 2020Assignee: Astellas Pharma Inc.Inventors: Takashi Sugane, Norio Asai, Hiroyuki Moritomo, Daisuke Yamashita, Naomi Hosogai
-
Patent number: 10514095Abstract: A control device for a continuously variable transmission mechanism of a vehicle includes: a stepwise variable transmission mechanism which is disposed in series with the continuously variable transmission mechanism, and which has at least two or more forward gear stages; and a controller configured to increase the belt capacities to be greater than the belt capacity set when an accelerator opening degree is zero, at least in a time period from a timing when the accelerator opening degree becomes zero, to a timing when a braking force is generated by a depression of a brake pedal, the controller being configured to set an increase amount with respect to the belt capacity set when the accelerator opening degree is zero, to a smaller value as a transmission gear ratio of the stepwise variable transmission mechanism is higher.Type: GrantFiled: September 6, 2016Date of Patent: December 24, 2019Assignees: JATCO LTD, NISSAN MOTOR CO., LTD.Inventors: Yoshinobu Kawamoto, Norio Asai, Hiroyasu Tanaka
-
Publication number: 20190202815Abstract: [Problem] To provide a compound useful as an MC4 receptor agonist. [Means for Solution] The present inventors studied MC4 receptor agonists, and have found that a piperazine derivative has an MC4 receptor agonistic action, thereby completing the present invention. The piperazine derivative of the present invention has an MC4 receptor agonistic action, and can be used as an agent for preventing or treating bladder and/or urinary tract diseases, in particular, underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-external urethral sphincter dyssynergia, and voiding dysfunctions in benign prostatic hyperplasia.Type: ApplicationFiled: July 18, 2017Publication date: July 4, 2019Applicant: Astellas Pharma Inc.Inventors: Takashi SUGANE, Norio ASAI, Hiroyuki MORITOMO, Daisuke YAMASHITA, Naomi HOSOGAI
-
Patent number: 10301286Abstract: To provide a compound which can be used as an MC4 receptor agonist. The present inventors have investigated MC4 receptor agonists, and have found that a piperazine derivative has an action related to the agonists, thereby completing the present invention. That is, the piperazine derivative of the present invention has an MC4 receptor agonistic action, and can be used as an agent for preventing or treating bladder and/or urinary tract diseases, in particular, underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-external urethral sphincter dyssynergia, and voiding dysfunctions in benign prostatic hyperplasia.Type: GrantFiled: August 2, 2016Date of Patent: May 28, 2019Assignee: Astellas Pharma Inc.Inventors: Takashi Sugane, Takuya Makino, Daisuke Yamashita, Yasuhiro Yonetoku, Daisuke Tanabe, Hisashi Mihara, Norio Asai, Kazuhiko Osoda, Takafumi Shimizu, Hiroyuki Moritomo, Keizo Sugasawa, Kyoichi Maeno, Naomi Hosogai
-
Publication number: 20180245691Abstract: A control device for a continuously variable transmission mechanism of a vehicle includes: a stepwise variable transmission mechanism which is disposed in series with the continuously variable transmission mechanism, and which has at least two or more forward gear stages; and a controller configured to increase the belt capacities to be greater than the belt capacity set when an accelerator opening degree is zero, at least in a time period from a timing when the accelerator opening degree becomes zero, to a timing when a braking force is generated by a depression of a brake pedal, the controller being configured to set an increase amount with respect to the belt capacity set when the accelerator opening degree is zero, to a smaller value as a transmission gear ratio of the stepwise variable transmission mechanism is higher.Type: ApplicationFiled: September 6, 2016Publication date: August 30, 2018Applicants: JATCO Ltd, NISSAN MOTOR CO., LTD.Inventors: Yoshinobu KAWAMOTO, Norio ASAI, Hiroyasu TANAKA
-
Publication number: 20180230131Abstract: [Problem] To provide a compound which can be used as an MC4 receptor agonist. [Means for Solution] The present inventors have investigated MC4 receptor agonists, and have found that a piperazine derivative has an action related to the agonists, thereby completing the present invention. That is, the piperazine derivative of the present invention has an MC4 receptor agonistic action, and can be used as an agent for preventing or treating bladder and/or urinary tract diseases, in particular, underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-external urethral sphincter dyssynergia, and voiding dysfunctions in benign prostatic hyperplasia.Type: ApplicationFiled: August 2, 2016Publication date: August 16, 2018Applicant: Astellas Pharma Inc.Inventors: Takashi SUGANE, Takuya MAKINO, Daisuke YAMASHITA, Yasuhiro YONETOKU, Daisuke TANABE, Hisashi MIHARA, Norio ASAI, Kazuhiro OSODA, Takafumi SHIMIZU, Hiroyuki MORITOMO, Keizo SUGASAWA, Kyoichi MAENO, Naomi HOSAGAI
-
Patent number: 9598434Abstract: Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.Type: GrantFiled: July 13, 2015Date of Patent: March 21, 2017Assignee: ASTELLAS PHARMA INC.Inventors: Hiroyuki Koshio, Norio Asai, Taisuke Takahashi, Takafumi Shimizu, Yasuhito Nagai, Keiko Kawabata, Karl Bruce Thor
-
Patent number: 9566974Abstract: A transmission controller executes synchronization shift of shifting a variator in a direction opposite to a speed ratio change direction of a sub transmission mechanism when shifting a sub transmission mechanism. When a gear position of the sub transmission mechanism is at the second gear position and an output increase request of a power source is made, the transmission controller prohibits the synchronization shift and shifts only the sub transmission mechanism from a second gear position to a first gear position.Type: GrantFiled: November 9, 2012Date of Patent: February 14, 2017Assignees: JATCO LTD, NISSAN MOTOR CO., LTD.Inventors: Hiroyasu Tanaka, Mamiko Inoue, Ryousuke Nonomura, Takuichiro Inoue, Norio Asai, Masato Mori, Satoru Ishii, Fumito Shinohara
-
Publication number: 20150315208Abstract: Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.Type: ApplicationFiled: July 13, 2015Publication date: November 5, 2015Applicant: ASTELLAS PHARMA INC.Inventors: Hiroyuki KOSHIO, Norio ASAI, Taisuke TAKAHASHI, Takafumi SHIMIZU, Yasuhito NAGAI, Keiko KAWABATA, Karl Bruce THOR
-
Patent number: 9108977Abstract: Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.Type: GrantFiled: September 13, 2012Date of Patent: August 18, 2015Assignee: ASTELLAS PHARMA INC.Inventors: Hiroyuki Koshio, Norio Asai, Taisuke Takahashi, Takafumi Shimizu, Yasuhito Nagai, Keiko Kawabata, Karl Bruce Thor
-
Publication number: 20140342876Abstract: A transmission controller executes synchronization shift of shifting a variator in a direction opposite to a speed ratio change direction of a sub transmission mechanism when shifting a sub transmission mechanism. When a gear position of the sub transmission mechanism is at the second gear position and an output increase request of a power source is made, the transmission controller prohibits the synchronization shift and shifts only the sub transmission mechanism from a second gear position to a first gear position.Type: ApplicationFiled: November 9, 2012Publication date: November 20, 2014Inventors: Hiroyasu Tanaka, Mamiko Inoue, Ryousuke Nonomura, Takuichiro Inoue, Norio Asai, Masato Mori, Satoru Ishii, Fumito Shinohara
-
Publication number: 20130059837Abstract: Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.Type: ApplicationFiled: September 13, 2012Publication date: March 7, 2013Applicant: ASTELLAS PHARMA INC.Inventors: Hiroyuki KOSHIO, Norio ASAI, Taisuke TAKAHASHI, Takafumi SHIMIZU, Yasuhito NAGAI, Keiko KAWABATA, Karl Bruce THOR
-
Patent number: 8360920Abstract: When a vehicle stops in a travel range, a transmission controller sets a subtransmission mechanism in a second speed interlocking condition in which a torque input into a continuously variable transmission is transmitted in a second gear position and both a frictional engagement element of a first gear position and a frictional engagement element of the second gear position are engaged, and when a predetermined condition is established while the vehicle is stationary, the transmission controller reduces an output shaft torque of the continuously variable transmission.Type: GrantFiled: July 14, 2010Date of Patent: January 29, 2013Assignee: Nissan Motor Co., Ltd.Inventors: Ryousuke Nonomura, Hiroyasu Tanaka, Takuichiro Inoue, Jouji Seki, Mamiko Inoue, Norio Asai, Seiichiro Takahashi
-
Publication number: 20130012496Abstract: Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.Type: ApplicationFiled: March 11, 2011Publication date: January 10, 2013Applicant: ASTELLAS PHARMA INC.Inventors: Hiroyuki Koshio, Norio Asai, Taisuke Takahashi, Takafumi Shimizu, Yasuhito Nagai, Keiko Kawabata, Karl Bruce Thor
-
Publication number: 20110269744Abstract: [Problem] Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. [Means for Solution] The present inventors have investigated compounds having a 5-HT2C receptor agonist activity, which is promising as an active ingredient of a pharmaceutical composition for treating or preventing incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like, and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention.Type: ApplicationFiled: March 9, 2011Publication date: November 3, 2011Applicant: ASTELLAS PHARMA INC.Inventors: Hiroyuki KOSHIO, Norio ASAI, Taisuke TAKAHASHI, Takafumi SHIMIZU, Yasuhito NAGAI, Keiko KAWABATA, Karl Bruce THOR
-
Patent number: 8044206Abstract: The invention provides a novel nitrogen-containing heterocyclic derivative having 2,6-disubstituted styryl and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the nitrogen-containing heterocyclic derivative and a pharmaceutically acceptable salt thereof, in particular, a pharmaceutical composition effective as a sodium channel inhibitor, having an excellent analgesic action especially on neuropathic pain with minimized side effects.Type: GrantFiled: March 5, 2004Date of Patent: October 25, 2011Assignees: Astellas Pharma Inc., Kotobuki Pharmaceutical Co., Ltd.Inventors: Kazumi Kikuchi, Makoto Oku, Jiro Fujiyasu, Norio Asai, Toshihiro Watanabe, Yukinori Nagakura, Hiroshi Tomiyama, Motoharu Sonegawa, Kazuo Tokuzaki, Yoshinori Iwai
-
Patent number: 7968552Abstract: A compound which can be used as a pharmaceutical, particularly a insulin secretion promoter or a agent for preventing/treating disease in which GPR40 is concerned such as diabetes or the like, is provided. It was found that an oxadiazolidinedione compound which is characterized by the possession of a benzyl or the like substituent binding to the cyclic group via a linker at the 2-position of the oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof, has excellent GPR40 agonist action. In addition, since the oxadiazolidinedione compound of the present invention showed excellent insulin secretion promoting action and blood glucose level-lowering action, it is useful as an insulin secretion promoter or an agent for preventing/treating diabetes.Type: GrantFiled: April 23, 2007Date of Patent: June 28, 2011Assignee: Astellas Pharma Inc.Inventors: Kenji Negoro, Fumiyoshi Iwasaki, Kei Ohnuki, Toshio Kurosaki, Yasuhiro Yonetoku, Norio Asai, Shigeru Yoshida, Takatoshi Soga
-
Publication number: 20110015834Abstract: When a vehicle stops in a travel range, a transmission controller sets a subtransmission mechanism in a second speed interlocking condition in which a torque input into a continuously variable transmission is transmitted in a second gear position and both a frictional engagement element of a first gear position and a frictional engagement element of the second gear position are engaged, and when a predetermined condition is established while the vehicle is stationary, the transmission controller reduces an output shaft torque of the continuously variable transmission.Type: ApplicationFiled: July 14, 2010Publication date: January 20, 2011Inventors: Ryousuke NONOMURA, Hiroyasu Tanaka, Takuichiro Inoue, Jouji Seki, Mamiko Inoue, Norio Asai, Seiichiro Takahashi
-
Patent number: 7855198Abstract: There is provided a compound having a capsaicin receptor VR1 inhibitory activity and useful as a therapeutic agent for various pains including inflammatory pain and neurogenic pain, migraine, cluster headache, bladder diseases including overactive bladder, and the like. A benzamide derivative or a salt thereof wherein a benzene ring is attached to a D ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring) through an amide bond, the benzene ring is directly bonded to an E ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring), and the benzene ring is further bonded to A (an amino moiety, a monocyclic or bicyclic heterocycle) through L (a lower alkylene).Type: GrantFiled: July 2, 2009Date of Patent: December 21, 2010Assignee: Astellas Pharma Inc.Inventors: Takahiro Kuramochi, Norio Asai, Kazuhiro Ikegai, Seijiro Akamatsu, Hironori Harada, Noriko Ishikawa, Shohei Shirakami, Satoshi Miyamoto, Toshihiro Watanabe, Tetsuo Kiso
-
Publication number: 20100216798Abstract: There is provided fused heterocycles of imidazopyridazine or pyrazolopyrimidine derivative represented by the formula (I), which have excellent Lck inhibitory activity and are useful for a medicament particularly an immunosuppressive agent. [wherein one of Y and Z is C atom, and the other is N atom; —X— is —N(R1)— or the like, —R1 represents hydrogen or the like, -A- represents bond or the like, —R2 is cycloalkyl, aryl or the like, -E- is bond or the like, —R3 is aryl, aromatic heterocycle or the like, —R4, —R5 and —R6 are the same or different, each being hydrogen or the like.Type: ApplicationFiled: July 27, 2006Publication date: August 26, 2010Applicant: ASTELLAS PHARMA INCInventors: Kazuo Nakai, Fumie Takahashi, Kazuya Fujita, Yoshihiro Kozuki, Koichiro Mukoyoshi, Masamichi Inami, Norio Asai